Regenerative Medicine Advanced Therapy for Kymriah

The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Novartis’ Kymriah (tisagenlecleucel) for an investigational new indication to treat patients with relapsed or refractory (r/r) follicular lymphoma (FL).

Kymriah, which is designed to be a one-time treatment, is the first-ever FDA-approved CAR-T cell therapy.

The potential approval in r/r FL will be the third indication for Kymriah, which also has indications in r/r paediatric and young adult acute lymphoblastic leukaemia (ALL), and r/r adult diffuse large B-cell lymphoma (DLBCL).

“This designation supports the advancement of Kymriah, which could potentially address an unmet need in certain patients with follicular lymphoma, as we strive to reimagine medicine at Novartis,” said John Tsai, Head of Global Drug Development and Chief Medical Officer of Novartis.

“These patients are often faced with the burden of several years of various treatments as their disease continues to progres.”

The FDA granted RMAT designation for Kymriah in FL based on preliminary clinical evidence from the ELARA clinical trial, an ongoing multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.

Kymriah was developed in collaboration with the Perelman School of Medicine at the University of Pennsylvania, a strategic alliance between industry and academia which was first-of-its-kind in CAR-T research and development.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Related news

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...